Logo image of NUVL

NUVALENT INC-A (NUVL) Stock Fundamental Analysis

USA - NASDAQ:NUVL - US6707031075 - Common Stock

99.32 USD
+1.15 (+1.17%)
Last: 10/31/2025, 8:04:02 PM
99.32 USD
0 (0%)
After Hours: 10/31/2025, 8:04:02 PM
Fundamental Rating

3

Taking everything into account, NUVL scores 3 out of 10 in our fundamental rating. NUVL was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NUVL as it has an excellent financial health rating, but there are worries on the profitability. NUVL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUVL had negative earnings in the past year.
NUVL had a negative operating cash flow in the past year.
In the past 5 years NUVL always reported negative net income.
In the past 5 years NUVL always reported negative operating cash flow.
NUVL Yearly Net Income VS EBIT VS OCF VS FCFNUVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

NUVL has a better Return On Assets (-33.00%) than 64.04% of its industry peers.
With a decent Return On Equity value of -36.54%, NUVL is doing good in the industry, outperforming 73.78% of the companies in the same industry.
Industry RankSector Rank
ROA -33%
ROE -36.54%
ROIC N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
NUVL Yearly ROA, ROE, ROICNUVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

NUVL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVL Yearly Profit, Operating, Gross MarginsNUVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for NUVL has been increased compared to 1 year ago.
NUVL has more shares outstanding than it did 5 years ago.
NUVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUVL Yearly Shares OutstandingNUVL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
NUVL Yearly Total Debt VS Total AssetsNUVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 41.58 indicates that NUVL is not in any danger for bankruptcy at the moment.
The Altman-Z score of NUVL (41.58) is better than 95.51% of its industry peers.
There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.58
ROIC/WACCN/A
WACCN/A
NUVL Yearly LT Debt VS Equity VS FCFNUVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 13.57 indicates that NUVL has no problem at all paying its short term obligations.
The Current ratio of NUVL (13.57) is better than 88.20% of its industry peers.
A Quick Ratio of 13.57 indicates that NUVL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 13.57, NUVL belongs to the top of the industry, outperforming 88.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.57
Quick Ratio 13.57
NUVL Yearly Current Assets VS Current LiabilitesNUVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

NUVL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.26%.
EPS 1Y (TTM)-76.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NUVL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.23% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.77%
EPS Next 2Y-19.05%
EPS Next 3Y-1.96%
EPS Next 5Y22.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVL Yearly Revenue VS EstimatesNUVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NUVL Yearly EPS VS EstimatesNUVL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVL Price Earnings VS Forward Price EarningsNUVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVL Per share dataNUVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.05%
EPS Next 3Y-1.96%

More info and screens

0

5. Dividend

5.1 Amount

NUVL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVALENT INC-A

NASDAQ:NUVL (10/31/2025, 8:04:02 PM)

After market: 99.32 0 (0%)

99.32

+1.15 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners107.08%
Inst Owner Change0.04%
Ins Owners2.86%
Ins Owner Change0.63%
Market Cap7.16B
Revenue(TTM)N/A
Net Income(TTM)-343343000
Analysts86
Price Target121.85 (22.68%)
Short Float %7.6%
Short Ratio11.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.46%
Min EPS beat(2)-10.33%
Max EPS beat(2)-6.58%
EPS beat(4)1
Avg EPS beat(4)-11.61%
Min EPS beat(4)-33.94%
Max EPS beat(4)4.41%
EPS beat(8)3
Avg EPS beat(8)-7.43%
EPS beat(12)6
Avg EPS beat(12)-3.48%
EPS beat(16)8
Avg EPS beat(16)-5.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.25%
PT rev (3m)3.47%
EPS NQ rev (1m)-0.47%
EPS NQ rev (3m)-8.18%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)-7.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.62
P/tB 7.62
EV/EBITDA N/A
EPS(TTM)-4.9
EYN/A
EPS(NY)-5.53
Fwd EYN/A
FCF(TTM)-3.32
FCFYN/A
OCF(TTM)-3.32
OCFYN/A
SpS0
BVpS13.03
TBVpS13.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33%
ROE -36.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.57
Quick Ratio 13.57
Altman-Z 41.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.95%
EPS Next Y-39.77%
EPS Next 2Y-19.05%
EPS Next 3Y-1.96%
EPS Next 5Y22.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-78.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.7%
EBIT Next 3Y-3.6%
EBIT Next 5YN/A
FCF growth 1Y-189.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-189.98%
OCF growth 3YN/A
OCF growth 5YN/A

NUVALENT INC-A / NUVL FAQ

What is the ChartMill fundamental rating of NUVALENT INC-A (NUVL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NUVL.


What is the valuation status of NUVALENT INC-A (NUVL) stock?

ChartMill assigns a valuation rating of 0 / 10 to NUVALENT INC-A (NUVL). This can be considered as Overvalued.


What is the profitability of NUVL stock?

NUVALENT INC-A (NUVL) has a profitability rating of 1 / 10.


What is the financial health of NUVALENT INC-A (NUVL) stock?

The financial health rating of NUVALENT INC-A (NUVL) is 8 / 10.


What is the earnings growth outlook for NUVALENT INC-A?

The Earnings per Share (EPS) of NUVALENT INC-A (NUVL) is expected to decline by -39.77% in the next year.